Another way to gauge Vascepa uptake is to look at Lovaza script declines. It makes sense that we will see a lack of Lovaza script refills before we see Vascepa scripts rise.
Lovaza most recent week: 91,128 versus 92,882 the week before and 97,168 the week before that. The delta between the two most recent weeks seems to be the intriguing number as we didnt see a rebound two weeks after the big drop from 97.1 to 92.8 but actually fell another 1,754 scripts. That 1,754 is the interesting number...
Hi Yellow. bluff
--- well sorry to throw a wrinkle into your theory of a gauge but you haven't factored in that some on Lovaza have switched to DS alternatives , particularly since GSK raised the price on Lovaza ( now $8 a day out of pocket ) and theres more insurance push back re off label scrips.
Not saying there is no cross over to Vascepa --- you will probably see that in the over 500 TG group ---just you have to account for cross over to DS alternatives if the patient has no co pays for TG's under 500 , particularly if she/he can't get a script for either Vascepa or Lovaza now
How are you doing on the Artic pure EPA ---those pills are HUGE . Did you ever get a script for Vascepa
Great news yellow thanks for sharing. Any data on scripts for tricor/trilipix? A decline in those would show a possible switch to Vascepa as well. This lovaza numbers show a probable 5,000 a week vascepa fill rate once the samples have dried up. Very encouraging this early on.
oh and have forgot aout the anchor market? ten fold that of what loveza and vascepa serve now...oh and loveza and its generics can't serve that market....this will be doing 5 bil in annual sales so let's see what bp wants to pony up and add to revs